Alameda, Calif.-based InSite Vision completed dual ophthalmic agents used in blepharitis Phase 3 clinical trial for two treatments for moderate-to-severe blepharitis.
Researchers evaluated AzaSite Plus and DexaSite, and found they did not completely resolve all symptoms. However, they did bring statistically significant improvements in symptoms at day 15. The study reaffirmed that blepharitis is chronic and persistent and may need a different clinical approach than finding a traditional cure.
InSite Vision's study is the largest, most quantitative clinical examination of blepharitis ever conducted. Currently, no pharmaceuticals are approved to help the more than 34 million Americans with the condition, which is characterized by chronic inflammation of the eyelid.
More Articles on Ophthalmology:
Case Western Reserve University Names Dr. Douglas Rhee Chair of Ophthalmology and Visual Sciences
Laurel Laser & Surgery Center in Pennsylvania Celebrates 10k Cataract Removals
Researchers Successfully Treat Blindness in Mice With Stem Cell Therapy